A Phase 1/2 interventional study of riboflavin ophthalmic solution, 0% dextran and UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA) in Hyperopia and Hyperopic Astigmatism, sponsored by Glaukos Corporation. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-26.
Sponsored by Glaukos Corporation · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Hyperopia with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Hyperopia · United States.
Among the 68 studies in Hyperopia with a site in United States, this one is the 54th largest by enrollment of the 54 interventional ones that give a count, is one of 2 that started in 2013, is one of 4 in phase 1/2, and was the 22nd registered.
156 studies on the registry are indexed under Hyperopia; 20 are open to participants now.
Browse Hyperopia studies →3 of the 68 studies in Hyperopia with a site in United States are open now. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 21–62 · Healthy volunteers
Ohio State University · Sites in United States
Ages 13 wk–19 wk
VIS, Inc. · Sites in United States, Canada
Ages 40+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Hyperopia studies recruiting now, 3 set no upper age limit and 5 stop at 75 or younger; 5 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 1 · Phase 4 4
First in 2001; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2 is below the median of 60 across 125 interventional studies indexed under Hyperopia.
Median enrollment 61 across the 54 interventional studies, 148 across the 14 observational. Of the 59 that completed or were terminated, 34 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 68 have an industry lead sponsor. The 10 most frequent:
Glaukos Corporation is the lead sponsor of 67 studies on the registry; 14 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 7 (54%) have results posted.
Glaukos Corporation has 1 study filed under Hyperopia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 68 studies in Hyperopia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objectives of this study are to evaluate the safety and efficacy, with regards to regression of refractive outcome, as measured by manifest refraction spherical equivalent (MRSE), of two treatment regimens for hyperopic and hyperopic astigmatic subjects: LASIK followed by cross-linking performed with the KXL System and Photrexa ZD™ (Riboflavin Ophthalmic Solution), as compared to LASIK alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Removal of contact lenses for the required period of time prior to the screening refraction:
Exclusion Criteria:
Ocular condition that may predispose the subject to future complications, for example:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Following LASIK, the corneal bed will be thoroughly coated with five drops of riboflavin ophthalmic solution, rinsed with saline solution, and the corneal flap repositioned. The eye will then be irradiated at 30 mW/cm2 for 2 minutes continuous UVA.
Drug: riboflavin ophthalmic solution, 0% dextran · Device: UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA) · Procedure: Laser-assisted in situ keratomileusis
Following LASIK, the corneal bed will be thoroughly coated with five drops of riboflavin ophthalmic solution, rinsed with saline solution, and the corneal flap repositioned. The eye will then be irradiated at 30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off.
Drug: riboflavin ophthalmic solution, 0% dextran · Device: UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off) · Procedure: Laser-assisted in situ keratomileusis
Eyes assigned to this arm will receive standard LASIK with no cross-linking.
Procedure: Laser-assisted in situ keratomileusis
Drug pages: Riboflavin · Dextrans
Also known as: Photrexa ZD
Also known as: KXL System
Also known as: KXL System
Also known as: LASIK
MRSE Regression
The co-primary efficacy endpoints are a comparison of MRSE regression in the refractive outcome between the LASIK only eyes and the LASIK with cross-linking eyes within each treatment type and duration (2 minutes continuous UVA or 3 minutes pulsed UVA cross-linking) expressed as the change between one week and six months, and one week and twelve months.
Time frame: one week to six months
MRSE Regression
The co-primary efficacy endpoints are a comparison of MRSE regression in the refractive outcome between the LASIK only eyes and the LASIK with cross-linking eyes within each treatment type and duration (2 minutes continuous UVA or 3 minutes pulsed UVA cross-linking) expressed as the change between one week and six months, and one week and twelve months.
Time frame: one week to twelve months
| Milestone | LASIK Followed by Cross-linking (Continuous Wave) | LASIK Followed by Cross-linking (Pulsed) | LASIK Only |
|---|---|---|---|
| Started | 0 | 2 | 0 |
| Completed | 0 | 2 | 0 |
| Not completed | 0 | 0 | 0 |
The co-primary efficacy endpoints are a comparison of MRSE regression in the refractive outcome between the LASIK only eyes and the LASIK with cross-linking eyes within each treatment type and duration (2 minutes continuous UVA or 3 minutes pulsed UVA cross-linking) expressed as the change between one week and six months, and one week and twelve months.
No measurements were reported for this outcome.
The co-primary efficacy endpoints are a comparison of MRSE regression in the refractive outcome between the LASIK only eyes and the LASIK with cross-linking eyes within each treatment type and duration (2 minutes continuous UVA or 3 minutes pulsed UVA cross-linking) expressed as the change between one week and six months, and one week and twelve months.
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LASIK Followed by Cross-linking (Continuous Wave) | — | — | — |
| LASIK Followed by Cross-linking (Pulsed) | — | 0/2 (0%) | 2/2 (100%) |
| LASIK Only | — | — | 2/2 (100%) |
| Event | LASIK Followed by Cross-linking (Continuous Wave) | LASIK Followed by Cross-linking (Pulsed) | LASIK Only |
|---|---|---|---|
| Vision blurredEye disorders | — | 1/2 | 1/2 |
| Foreign body sensation in eyeEye disorders | — | 1/2 | 1/2 |
| PhotophobiaEye disorders | — | 1/2 | 1/2 |
| Conjunctival hyperaemiaEye disorders | — | 0/2 | 1/2 |
| Dry eyeEye disorders | — | 0/2 | 1/2 |
| Eye irritationEye disorders | — | 1/2 | 0/2 |
| Corneal flap complicationInjury, poisoning and procedural complications | — | 1/2 | 1/2 |
| Age, Categorical(Participants) | LASIK Followed by Cross-linking (Continuous Wave) | LASIK Followed by Cross-linking (Pulsed) | LASIK Only | Total |
|---|---|---|---|---|
| <=18 years | — | 0 | — | 0 |
| Between 18 and 65 years | — | 2 | — | 2 |
| >=65 years | — | 0 | — | 0 |
| Sex: Female, Male(Participants) | LASIK Followed by Cross-linking (Continuous Wave) | LASIK Followed by Cross-linking (Pulsed) | LASIK Only | Total |
|---|---|---|---|---|
| Female | — | 1 | — | 1 |
| Male | — | 1 | — | 1 |
| Race (NIH/OMB)(Participants) | LASIK Followed by Cross-linking (Continuous Wave) | LASIK Followed by Cross-linking (Pulsed) | LASIK Only | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | — | 0 | — | 0 |
| Asian | — | 0 | — | 0 |
| Native Hawaiian or Other Pacific Islander | — | 0 | — | 0 |
| Black or African American | — | 0 | — | 0 |
| White | — | 2 | — | 2 |
| More than one race | — | 0 | — | 0 |
| Unknown or Not Reported | — | 0 | — | 0 |
The record gives a start of Aug 2013, a primary completion of Feb 2015 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Riboflavin · Dextrans